跳至主要内容
临床试验/CTRI/2011/06/001804
CTRI/2011/06/001804已完成2 期

A double blind placebo controlled clinical trial to evaluate the efficacy and safety of Shatavari in Menstrual irregularity - Nil

The Himalaya Drug Company0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Females above the age of 45 with postmenopausal symptoms like hot flashes, night sweats, dry itchy skin, sleep disturbances, irritability, joint pain, anxiety or depression will be included in the study.

排除标准

  • Subjects suffering from serious life threatening disorders or participated in a similar study within past 1 month will be excluded from the study.

研究者

相似试验